This is exactly the point I raised a little while ago. Whilst Omnicar has been put on the back burner and cellpryme has seen no deal to date, the market has well and truly factored them out of our market cap.
All eyes are on PTX-100 and the potential for a registration study and rightfully so, we need it to kick some goals soon!
However, should we see any positive progressions with Omnicar or cellpryme I think you could expect a handy re-rate. It has not been an easy hold for many of us!
Ann: March 2024 Quarterly Update and Appendix 4C, page-13
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
